D-dimer is derived from the cross-linked fibrin clot dissolved by plasmin. It mainly reflects the lytic function of fibrin. It is mainly used in the diagnosis of venous thromboembolism, deep vein thrombosis and pulmonary embolism in clinical practice. D-dimer qualitative test is negative, if quantitative test should be less than 200μg/L.

Increased D-dimer or positive test results are often seen in diseases related to secondary hyperfibrinolysis, such as hypercoagulable state, disseminated intravascular coagulation, renal disease, organ transplant rejection, and thrombolytic therapy. In addition, when there is activated thrombosis in the body's blood vessels, or diseases accompanied by fibrinolytic activity, D-dimer will also be significantly increased. Common diseases such as myocardial infarction, pulmonary embolism, lower extremity deep vein thrombosis, cerebral infarction Etc.; some infections, surgery, tumor diseases, and tissue necrosis also lead to increased D-dimer; in addition, some human autoimmune diseases, such as rheumatic endocarditis, rheumatoid arthritis, systemic Lupus erythematosus, etc., may also cause increased D-dimer.

In addition to diagnosing diseases, the quantitative detection of D-dimer can also quantitatively reflect the thrombolytic effect of drugs in clinical practice. Aspects of diseases, etc., are all helpful.

In the case of elevated D-dimer, the body is at a high risk of thrombosis. At this time, the primary disease should be diagnosed as soon as possible, and the thrombosis prevention program should be started according to the DVT score. Some drugs can be selected for anticoagulation therapy, such as subcutaneous injection of low molecular weight heparin calcium or rivaroxaban, which have a certain preventive effect on the formation of thrombosis. Those with thrombotic lesions need to thrombolytic tumor as soon as possible within the golden time, and Periodically review D-dimer.